Taofeek Owonikoko MD, PhD
The monoclonal anti-PD-1 antibody cemiplimab (Libtayo) continued to demonstrate considerable antitumor activity and durable responses in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), according to follow-up data from a phase I trial presented at the 2018 ESMO Congress.1
Across the entire population of this combined analysis, the overall response rate (ORR) at a median follow-up of 8.9 months was 47% (95% CI, 38%-47%).2
The complete response (CR) rate was 4% and the partial response (PR) rate was 44%, and the duration of response (DOR) ranged from 1 month to over 15 months. Moreover, 61% of patients had a DOR ≥6 months.
Although the disease has a surgical cure rate upwards of 95%, there are an estimated 3932 to 8791 disease-related deaths in the United States in 2012.
... to read the full story